Monopar Therapeutics Inc.
MNPR
$59.27
-$1.72-2.82%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.21M | 1.50M | 1.50M | 1.58M | 1.15M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.16M | 4.09M | 3.23M | 3.22M | 11.07M |
| Operating Income | -6.16M | -4.09M | -3.23M | -3.22M | -11.07M |
| Income Before Tax | -5.20M | -3.44M | -2.45M | -2.63M | -10.93M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.20M | -3.44M | -2.45M | -2.63M | -10.93M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.20M | -3.44M | -2.45M | -2.63M | -10.93M |
| EBIT | -6.16M | -4.09M | -3.23M | -3.22M | -11.07M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.61 | -0.48 | -0.35 | -0.38 | -2.23 |
| Normalized Basic EPS | -0.38 | -0.30 | -0.22 | -0.23 | -1.39 |
| EPS Diluted | -0.61 | -0.48 | -0.35 | -0.38 | -2.23 |
| Normalized Diluted EPS | -0.38 | -0.30 | -0.22 | -0.23 | -1.39 |
| Average Basic Shares Outstanding | 8.53M | 7.12M | 7.00M | 6.99M | 4.90M |
| Average Diluted Shares Outstanding | 8.53M | 7.12M | 7.00M | 6.99M | 4.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |